Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
Study Details
Study Description
Brief Summary
This protocol aims to evaluate the efficacy of a theoretically and stakeholder informed patient-centered genetic Interactive Health Communication Application to increase patient understanding of, and affective and behavioral responses to genetic testing. The study investigators hypothesize that the intervention will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in performance of risk reducing health behaviors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
As clinical practice increasingly use multi-gene testing, many patients are left with unknowns after genetic testing. Many have results that are unclear and may or may not be associated with any risk for cancer (Variants of Uncertain Significance), or mutations in genes with very limited information about disease risk or the best medical management. Importantly, many of these uncertainties will be clarified over time, but there is a need for effective ways of communicating these updates to patients who had testing months or years ago. In some cases, there may be multiple updates over time. To address this, this study will provide patients access, using an Interactive Health Communication Application, MyCancerGene, to information about their genetic testing, their specific results and the implications, the ability to print reports and other materials for their relatives and other health care providers and to assess if there has been a change in the personal or family history. Additionally, patients can contact their genetic provider through MyCancerGene and the cancer genetics team can send out updates to patients about their individual results or about new information about risk estimates or screening recommendations. The study investigators hypothesize that MyCancerGene will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in cancer screening and risk reducing health behaviors. After 12 months, all patients will have access to MyCancerGene, which will aid in understanding who benefits most and least from this intervention.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention Group Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application. |
Behavioral: MyCancerGene
Interactive Health Communication Application
|
| No Intervention: Usual Care Group Individuals randomized to this arm will receive the standard clinical practice. |
Outcome Measures
Primary Outcome Measures
- The KnowGene Scale [Baseline - 18 Months]
Change in Knowledge. Score Range = 0-16. Higher score = Better outcome
- Patient Reported Outcomes Measurement Information System (PROMIS) [Baseline - 18 Months]
Change in General Anxiety and Depression. Score Range = 4-20 for Anxiety/4-20 for Depression. Lower score = Better outcome
Secondary Outcome Measures
- Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA) [Baseline - 18 Months]
Change in Uncertainty. Score Range = 0-85. Lower score = Better outcome
- Impact of Events Scale (IES) [Baseline - 18 months]
Change in Disease-Specific Distress. Score Range =0-40. Lower score = Better outcome
- Test Result Recall [Baseline - 18 months]
Single item assessing participants' ability to accurately recall their genetic test result. Single answer multiple choice: Positive, Negative, Variant of Uncertain Significance
- Perceptions of Genetic Disease [Baseline - 18 months]
Quantitative scales assessing changes in perceived risk, timeline and utility.
- Behavioral Risk Factor Surveillance System Questionnaire (BRFSS) [Baseline - 18 months]
Changes in modifiable cancer lifestyle behaviors. Yes/No responses.
- Health and Diet Survey Dietary Guidelines Supplement [Baseline - 18 months]
Changes in diet and exercise. Yes/No responses.
- Sharing Genomic Information with Relatives (adapted from the PHENX Toolkit) [Baseline - 18 months]
Assesses the number of relatives and health care providers patients share genetic test results with
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years of age or older
-
English Speaking
-
Male or Female
-
Internet and/or mobile access
-
Previously received clinical genetic counseling and testing for hereditary cancer syndromes (up to 60 days prior to recruitment)
Exclusion Criteria:
•No internet and/or mobile access
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Abramson Cancer Center at the University of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 |
Sponsors and Collaborators
- Abramson Cancer Center of the University of Pennsylvania
- American Cancer Society, Inc.
Investigators
- Principal Investigator: Angela R Bradbury, MD, University of Pennsylvania
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UPCC 10919
- 832628